NL-OMON24002已完成不适用
Phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- VALT
- 入组人数
- 216
研究概览
简要总结
only on phase 2 study by P Baas et al 2005 Lung Cancer
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Good condition (PS 0-2);
- •2. First line therapy with pemetrexed minimum of 4 courses;
排除标准
- •1. Inaqdequate measures for birth control;
- •2. Polyneuropathy > grade 1;
研究者
相似试验
已完成
3 期
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyMultiple MyelomaNCT00083551University of Arkansas668
已完成
2 期
Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's MacroglobulinemiaWaldenstrom MacroglobulinemiaNCT00083707University of Arkansas40
已完成
不适用
Phase III trial of the anti-angiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapyCancerISRCTN13632914ederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT) (The Netherlands)216
已完成
2 期
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix CancerCarcinoma of the AppendixColorectal CancerNCT00310076Wake Forest University Health Sciences29
已完成
2 期
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the UterusRecurrent Uterine Corpus SarcomaUterine CarcinosarcomaNCT00025506National Cancer Institute (NCI)55